TCP
AMAG

Tourbillon Capital Partners’s AMAG Pharmaceuticals AMAG Stock Holding History

Tourbillon Capital Partners’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-100,000
Closed -$3.19M – 116
2014
Q3 		$3.19M Buy
+100,000
New +$2.13M 0.12% 78

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tourbillon Capital Partners's AMAG Position: Q3 2015 in Review

Tourbillon Capital Partners sold out of AMAG Pharmaceuticals (AMAG) in Q3 2015, closing a stake of 452,000 shares — an estimated $31.2M sold.

Tourbillon Capital Partners first reported a position in AMAG in Q3 2014 and held it in 3 quarters. The position peaked at $31.2M in Q2 2015. 210 funds tracked by Wall St. Rank hold AMAG as of Q3 2015.

  • Tourbillon Capital Partners reported no remaining AMAG Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Tourbillon Capital Partners sold 452,000 AMAG Pharmaceuticals shares in Q3 2015, an estimated $31.2M.
  • Tourbillon Capital Partners first reported a position in AMAG Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • Tourbillon Capital Partners's AMAG Pharmaceuticals position peaked at $31.2M in Q2 2015.
  • 210 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2015.

Based on Tourbillon Capital Partners's 13F filing for Q3 2015, filed 16 Nov 2015.